Ignite Creation Date:
2024-05-06 @ 7:33 PM
Last Modification Date:
2024-10-26 @ 3:09 PM
Study NCT ID:
NCT06055673
Status:
RECRUITING
Last Update Posted:
2023-09-28
First Post:
2023-09-20
Brief Title:
Angiotensin Converting Enzyme rs 1799752 Gene Polymorphism and Development of In-Stent Restenosis in Patients With Stable Coronary Artery Diseases in Sohag Hospital University
Sponsor:
Sohag University
Organization:
Sohag University
Study Overview
Official Title:
Angiotensin Converting Enzyme rs 1799752 Gene Polymorphism and Development of In-Stent Restenosis in Patients With Stable Coronary Artery Diseases in Sohag Hospital University
Status:
RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
One of the most common medical approaches to the treatment of coronary artery disease CAD is the percutaneous coronary intervention PCI which became frequent due to high efficiency and safety of this procedure Modern-day advances in pharmacotherapy and the device innovations over the last thirty years enhanced the benign outcomes of patients with unstable or multivessel CAD and multiple co-morbidities treated by PCI
In-stent restenosis ISR is a recognized complication following percutaneous coronary intervention in which the luminal diameter is narrowed through neointimal hyperplasia and vessel remodeling Although rates of ISR have decreased in most recent years owing to newer generation drug-eluting stents thinner struts and better intravascular imaging modalities ISR remains a prevalent dilemma that proves to be challenging to manage Several factors have been proposed to contribute to ISR formation including mechanical stent characteristics technical factors during the coronary intervention and biological aspects of drug-eluting stents identification of risk factors and mechanisms underlying ISR is necessary for understanding the process the risk stratification and optimal treatment development Restenosis as a physiological response to mechanical damage involves two mechanisms which are neointimal hyperplasia and vessel remodeling 3 Several factors such as age diabetes mellitus hypertension stenting of small coronary arteries and final total length of stents have been shown to be associated with an elevated risk of restenosis
In-stent restenosis ISR is a recognized complication following percutaneous coronary intervention in which the luminal diameter is narrowed through neointimal hyperplasia and vessel remodeling Although rates of ISR have decreased in most recent years owing to newer generation drug-eluting stents thinner struts and better intravascular imaging modalities ISR remains a prevalent dilemma that proves to be challenging to manage Several factors have been proposed to contribute to ISR formation including mechanical stent characteristics technical factors during the coronary intervention and biological aspects of drug-eluting stents identification of risk factors and mechanisms underlying ISR is necessary for understanding the process the risk stratification and optimal treatment development Restenosis as a physiological response to mechanical damage involves two mechanisms which are neointimal hyperplasia and vessel remodeling 3 Several factors such as age diabetes mellitus hypertension stenting of small coronary arteries and final total length of stents have been shown to be associated with an elevated risk of restenosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None